The pharmaceutical industry won another 60 billion yuan to support the capital companies value implementation more.

The "Policy" stated that in 2009 and 2010, the government will invest 32.8 billion yuan and 30 billion yuan respectively in major projects. This involves the creation of major new drugs in the medical field, and prevention of major infectious diseases such as AIDS and viral hepatitis. Wait.

"Last year, the National Development and Reform Commission, the Ministry of Science and Technology, and the Ministry of Finance began organizing the establishment of major science and technology projects and research work. Of the 11 major scientific and technological special projects, two involved pharmaceuticals. We also participated in the project as representatives of enterprises. Demonstration work.” Yesterday, Wang Zhiguang, president of the revised pharmaceutical industry, told CBN reporters that from now on, the creation of major new drugs and the prevention and control of major infectious diseases are still on the list.

Apart from the fact that no major changes have been made to the project, the intensity of the investment has doubled with the originally planned plan, which is undoubtedly a major positive news for the entire pharmaceutical industry.

Chen Miao, general manager of Baiyunshan Pharmaceutical Co., Ltd. (000522.SZ, hereinafter referred to as “Baiyun Mountain”) told CBN reporters that “the sixth clause of the new policy should be said to be the most attractive to the company.” This article clearly stipulates the creation of A good market environment, actively nurturing market demand for biological products, improving market access policies for biological products, strengthening protection of intellectual property rights, and standardizing the order of market competition.

"As a company, the most concerned is the guarantee of the market order and intellectual property rights issues. How some new drugs can be linked to the market soon after R&D, and funding support for R&D projects is second only." Chen Mao said.

At present, biotechnology companies are mainly concentrated in Europe and the United States, accounting for 76% of the global total. European and American companies account for 93% of global biotechnology company sales, while sales in the Asia Pacific region account for only about 3% of the world's total. The United States is the leading biotechnology industry and far ahead of other countries. Its products and market sales account for more than 70% of the world's total.

After years of development and market competition, many developed countries have gradually formed bio-industrial agglomerations in regions where technology, talents, and capital are intensive, resulting in a relatively complete biopharmaceutical industrial chain and industrial cluster.

Chen Mao said that this is inseparable from the government's support. As a highly capital-intensive, high-risk, high-talent-intensive industry, the country's industrial support policy is undoubtedly a pinch-out agent, allowing this industry to accelerate development. power.